Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: Comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Wong, Carlos K H ^a   Lam, Cindy L K ^a   Wan, Y F ^a   Fong, Daniel Y T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colonoscopy; Colorectal cancer; Cost effectiveness; Fecal occult blood testing; Mass screening

Indexed keywords

GUAIAC;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CHINESE; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HONG KONG; HUMAN; IMMUNOLOGICAL PROCEDURES; MALE; OCCULT BLOOD; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; COLORECTAL NEOPLASMS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FECES; MASS SCREENING; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; FEMALE; GUAIAC; HONG KONG; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; QUALITY-ADJUSTED LIFE YEARS;

EID: 84944885048     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1730-y     Document Type: Article

References (73)

1. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-Term Mortality after Screening for Colorectal Cancer. N Engl J Med. 2013;369(12):1106-14.
2. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008. Am J Gastroenterol. 2009;104(3):739-50.
3. Muller AD, Sonnenberg A. Protection by Endoscopy Against Death From Colorectal Cancer: A Case-control Study Among Veterans. Arch Intern Med. 1995;155(16):1741-8.
4. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of Colonoscopy and Death From Colorectal Cancer. Ann Intern Med. 2009;150(1):1-8.
5. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer. N Engl J Med. 2000;343(22):1603-7.
6. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal Cancer Mortality: Effectiveness of Biennial Screening for Fecal Occult Blood. J Natl Cancer Inst. 1999;91(5):434-7.
7. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71.
8. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472-7.
9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood. N Engl J Med. 1993;328(19):1365-71.
10. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al. Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. N Engl J Med. 2012;366(8):697-706.
11. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of Screening for Colorectal Cancer in the General Population. JAMA. 2000;284(15):1954-61.
12. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659-69.
13. Tsoi KKF, Ng SSM, Leung MCM, Sung JJY. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther. 2008;28(3):353-63.
14. Woo PP, Kim JJ, Leung GM, Woo PPS, Kim JJ, Leung GM. What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol. 2007;25(6):617-24.
15. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal (reference N1618). London: NICE; 2008.
16. Tappenden P, Chilcott J, Eggington S, Sakai H, Karnon J, Patnick J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007;56(5):677-84.
17. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ. 1998;7(1):21-9.
18. Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of screening for colorectal cancer. CMAJ. 2010;182(12):1307-13.
19. Sharaf RN, Ladabaum U. Comparative Effectiveness and Cost-Effectiveness of Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies. Am J Gastroenterol. 2013;108(1):120-32.
20. Sung JJY, Lau JYW, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871-6.
21. Sonnenberg FA, Beck JR. Markov Models in Medical Decision Making: A Practical Guide. Med Decis Mak. 1993;13(4):322-38.
22. Sung JJY, Chan FKL, Leung WK, Wu JCY, Lau JYW, Ching J, et al. Screening for colorectal cancer in Chinese: Comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology. 2003;124(3):608-14.
23. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut. 2002;51 suppl 5:v6-9.
24. Greene FL, Page DL, Fleming ID, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th ed. New York: Springer Publishers; 2002.
25. Leshno M, Halpern Z, Arber N. Cost-Effectiveness of Colorectal Cancer Screening in the Average Risk Population. Health Care Manag Sci. 2003;6(3):165-74.
26. SEER Cancer Statistics Review, 1975-2007 [ http://seer.cancer.gov/csr/1975_2007/ ]. Accessed 28 March 2014.
27. Hong Kong Cancer Registry Web Site [ http://www.ha.org.hk/cancereg ]. Accessed 28 March 2014.
28. Hong Kong Census and Statistics Department. Projected Hong Kong life tables, 2007-2036. Hong Kong: Government Printers; 2007.
29. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2008;149(9):627-37.
30. Macafee DAL, Waller M, Whynes DK, Moss S, Scholefield JH. Population screening for colorectal cancer: the implications of an ageing population. Br J Cancer. 2008;99(12):1991-2000.
31. Lisi D, Hassan CC, Crespi M. Participation in colorectal cancer screening with FOBT and colonoscopy: An Italian, multicentre, randomized population study. Dig Liver Dis. 2010;42(5):371-6.
32. Hol L, Van Leerdam ME, Van Ballegooijen M, Van Vuuren AJ, Van Dekken H, Reijerink JCIY, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(01):62-8.
33. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal cancer screening pilot programme: results of the first round. J Med Screen. 2008;15(3):143-8.
34. Weller D, Moss S, Butler P, Campbell C, Coleman D, Melia J, et al. English Pilot of Bowel Cancer Screening: an evaluation of the second round. Final Report to the Department of Health. London: Institute of Cancer Research; 2006.
35. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-Term Efficacy of Sigmoidoscopy in the Reduction of Colorectal Cancer Incidence. J Natl Cancer Inst. 2003;95(8):622-5.
36. Wong BC, Chan AO, Wong KW, Ching CK, Wong WM, Tam S, et al. A pilot study of participation in faecal occult blood testing and screening colonoscopy after health education in Hong Kong. Eur J Cancer Prev. 2005;14(2):181-4.
37. Wong WM, Lam SK, Cheung KL, Tong TSM, Rozen P, Young GP, et al. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer. 2003;97(10):2420-4.
38. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for Colorectal Cancer: A Targeted, Updated Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):638-58.
39. Macrae FA, Tan KG, Williams CB. Towards safer colonoscopy: a report on the complications of 5000 diagnostic or therapeutic colonoscopies. Gut. 1983;24(5):376-83.
40. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications of screening flexible sigmoidoscopy. Gastroenterology. 2002;123(6):1786-92.
41. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"--SCORE. J Natl Cancer Inst. 2002;94(23):1763-72.
42. Nelson DB, McQuaid KR, Bond JH, Lieberman DA, Weiss DG, Johnston TK. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc. 2002;55(3):307-14.
43. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based Study. J Natl Cancer Inst. 2003;95(3):230-6.
44. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al. Complications of Colonoscopy in an Integrated Health Care Delivery System. Ann Intern Med. 2006;145(12):880-6.
45. Rathgaber SW, Wick TM. Colonoscopy completion and complication rates in a community gastroenterology practice. Gastrointest Endosc. 2006;64(4):556-62.
46. Ko CW, Riffle S, Shapiro JA, Saunders MD, Lee SD, Tung BY, et al. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc. 2007;65(4):648-56.
47. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17.
48. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection From Colorectal Cancer After Colonoscopy: A Population-Based, Case-Control Study. Ann Intern Med. 2011;154(1):22-30.
49. Wong CKH, Lam CLK, Poon JTC, McGhee SM, Law WL, Kwong DLW, et al. Direct Medical Costs of Care for Chinese Patients with Colorectal Neoplasia: a Health Care Service Provider Perspective. J Eval Clin Pract. 2012;18(6):1203-10.
50. Cheng KC, Yeung YP, Lau PYY, Meng WCS. Surveillance and outcome of liver metastasis in patients with colorectal cancer who had undergone curative-intent operation. Hong Kong Med J. 2008;14(6):432-6.
51. Hospital Authority. List of charges: S.S. No. 4 to Gazette No. 44/1996 and G.N. 2028 to Gazette No. 13/2003. Hong Kong: Hong Kong Government Printers; 1996, 2003.
52. Lam CLK, Brazier J, McGhee SM. Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population. Value Health. 2008;11(2):295-303.
53. McGhee SM, Brazier J, Lam CLK, Wong LC, Chau J, Cheung A, et al. Quality-adjusted life years: population-specific measurement of the quality component. Hong Kong Med J. 2011;17 Suppl 6:17-21.
54. Wong CKH, Mulhern B, Wan Y-F, Lam CLK. Responsiveness was similar between direct and mapped SF-6D in colorectal cancer patients who declined. J Clin Epidemiol. 2014;67(2):219-27.
55. Wong CKH, Lam CLK, Poon JTC, Kwong DLW. Clinical Correlates of Health Preference and Generic Health-related Quality of Life in Patients with Colorectal Neoplasms. PLoS One. 2013;8(3):e58341.
56. Cantor SB. Cost - Effectiveness Analysis, Extended Dominance, and Ethics. Med Decis Mak. 1994;14(3):259-65.
57. Barton GR, Briggs AH, Fenwick EAL. Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI). Value Health. 2008;11(5):886-97.
58. Stinnett AA, Mullahy J. Net Health Benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998;18(2):S68-80.
59. Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JDF, van Ballegooijen M. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer. 2011;117(18):4166-74.
60. Dan YY, Chuah BYS, Koh DCS, Yeoh KG. Screening Based on Risk for Colorectal Cancer Is the Most Cost-Effective Approach. Clin Gastroenterol Hepatol. 2012;10(3):266-271.e266.
61. Vijan S, Hwang I, Inadomi J, Wong RKH, Choi JR, Napierkowski J, et al. The Cost-Effectiveness of CT Colonography in Screening for Colorectal Neoplasia. Am J Gastroenterol. 2007;102(2):380-90.
62. Ladabaum U, Phillips KA. Colorectal Cancer Screening: Differential Costs for Younger Versus Older Americans. Am J Prev Med. 2006;30(5):378-84.
63. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126(5):1270-9.
64. Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer. 2012;106(5):805-16.
65. Briggs AH. Handling Uncertainty in Cost-Effectiveness Models. PharmacoEconomics. 2000;17(5):479-500.
66. Berchi C, Bouvier V, Réaud J-M, Launoy G. Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Econ. 2004;13(3):227-38.
67. van Rossum LGM, van Rijn AF, Verbeek ALM, van Oijen MGH, Laheij RJF, Fockens P, et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: A cost-effectiveness analysis. Int J Cancer. 2011;128(8):1908-17.
68. Lejeune C, Dancourt V, Arveux P, Bonithon-Kopp C, Faivre J. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int J Technol Assess Health Care. 2010;26(01):40-7.
69. Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, John DJBS. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. MJA. 2011;194(4):180-5.
70. O'Leary BA, Olynyk JK, Neville AM, Platell CF. Cost-effectiveness of colorectal cancer screening: Comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol. 2004;19(1):38-47.
71. Graves N, McKinnon L, Leggett B, Newman B. Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia. Aust New Zealand Health Policy. 2005;2(1):10.
72. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med. 2010;7(11):e1000370.
73. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650-7.